Search Results

< Back The FDA is Defining Genome Editing Safety Jun 29, 2026 Over the past several weeks, we've discussed how advances in gene delivery are impacting CMC. Our highlighted topics, ranging from mRNA and lipid nanoparticles to in-vivo CAR-T therapies, consistently center around analytical characterization, comparability, and manufacturing readiness. Today, we want to shine that same light on genome editing. This spring, the FDA released draft guidance on the safety assessment of genome editing products using next-generation sequencing (NGS). Applying to ex-vivo and in-vivo gene editing approaches, the recommendations affect virtually every genome editing program entering clinical development, including CRISPR-engineered cell therapies, TALENs, in-vivo gene editing delivered by viral vectors or lipid nanoparticles, and newer editing platforms such as base editing. In this guidance, the FDA asserts the expectation that sponsors establish a scientifically justified NGS (next-gen sequencing) strategy early, i.e., before entering the clinic. The guidance outlines recommendations for evaluating off-target editing, chromosomal alterations, genomic integrity, sequencing strategies, and the information expected in IND and BLA submissions. More technically, the FDA emphasizes that sequencing should be fit for purpose rather than relying on a single universal assay. This means that sequencing approaches must be selected according to the specific editing platform and clinical context rather than applying a single analytical strategy across all products. Lastly, the guidance also recognizes bioinformatics as an essential component of genome editing safety assessment, placing expectations on data processing, variant calling, and interpretation alongside laboratory testing. As gene therapies move into the clinic, regulators expect sponsors to characterize editing outcomes with greater depth and scientific rigor, for the safety of patients. All aforementioned studies directly influence downstream process and manufacturing development, comparability planning, and regulatory submissions, and thus, the FDA but also our own CMC experts consistently recommend that these studies be completed early enough to support original IND submissions rather than being added later in development . At Pharmefex, we keep highlighting this, and we see this as a continuation of the broader evolution across advanced therapies. Our team supports developers of viral vectors, lipid nanoparticles, cell and gene therapies, and genome editing products by integrating CMC strategy, analytical development, and regulatory planning from the earliest stages . In summary, the FDA provides a framework for demonstrating product safety and genomic integrity. However, it is programs that utilize Pharmefex’ CMC support to build sequencing strategy, off-target assessment, and genomic integrity from the outset and implement it into their CMC strategy early, that will be better prepared for regulatory review and clinical progression. #Pharmefex #CMC #NGS #safety #genomeediting #DahliaConsulting #CGT #genetherapy Sources FDA Draft Guidance: Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing (FDA-2026-D-1255, April 14, 2026) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-assessment-genome-editing-human-gene-therapy-products-using-next-generation-sequencing Federal Register Notice (Comment deadline: July 14, 2026) https://www.federalregister.gov/documents/2026/04/15/2026-07285/safety-assessment-of-genome-editing-in-human-gene-therapy-products-using-next-generation-sequencing Regulatory Affairs Professionals Society (RAPS): FDA Draft Guidance on NGS for Genome Editing Safety Assessment FDA drafts guidance on using next-generation sequencing to assess gene therapy safety | RAPS Previous Next

Latest Biopharmaceutical News from Pharmefex Latest News 6/29/26 The FDA is Defining Genome Editing Safety Read More 6/17/26 Bispecific antibodies are an expanding therapeutic approach with a key challenge in CMC Read More 6/10/26 CAR-T Meets LNP: A Familiar Platform with a New CMC Challenge Read More 5/25/26 CGT Regulatory Flexibility and Global Harmonization Read More 5/22/26 mRNA/LNP Manufacturing: From Pandemic Platform to Industrial Discipline Read More 5/15/26 ADCs: A Deeper Look at Antibody-Drug Conjugates and Why CMC Preparedness Is Everything Read More 5/15/26 ADCs: Why the Most Exciting Modality in Oncology Is Also the Most CMC-Demanding Read More 1/28/26 ADCs: Manufacturing Challenges and Opportunities Read More 1/21/26 Early CMC readiness is front and center across the entire industry Read More 1/12/26 Supply chain resilience is becoming a manufacturing footprint decision Read More 1/5/26 CDMO strategy is one of the most important levers in CMC Read More 9/30/25 Pharmefex Brief on FDA PreCheck and AMT Read More 7/16/25 What the HHS Layoffs Mean for Biotech and What Companies Should Do Now Read More 6/12/25 Why Including Pregnant Women in Clinical Trials Is Essential for Ethical and Effective Drug Development Read More 6/10/25 Why Biotech Developers Must Act Now on Nitrosamine Risk Management Read More 6/4/25 Why Outsourced Project Management and Regulatory Compliance Are the Future of Biotech Read More 5/21/25 The Rise of ADCs. Why Outsourcing and Supply Chain Diversification Are Critical to Success Read More 5/13/25 Navigating the Complexities of CMC Strategy in Cell and Gene Therapy Development Read More 4/30/25 FDA Endorses Shift Toward Non-Animal Testing. A Transformative Step in Drug Development Read More 4/22/25 ICH Publishes Revised Q1A(R3) Stability Guideline: Strategic Considerations Read More

Explore our Publications & Presentations by leading Biopharmaceutical‬ consultants. Discover insights on project, supply chain management and CMC! Publications & Presentations Pharmefex's Compliance Readiness Checklist 2025 Pharmefex Compliance Readiness Checklist Read More Overcoming challenges in technology transfer for cell therapies 2015 PDA Annual Meeting, 3/26-3/18, Las Vegas, NV Read More Improving the success of your academia to industry transfers for autologous cell therapies 2015 IBC Conference on Cell and Gene Therapy - Alexandria, VA 9/29-10/2 Read More A Roadmap for efficient transition from Development to Commercial 2016 BPI West Conference, Oakland, CA. Read More

Guidance Documents from Pharmefex Guidance Documents General Documents Guidance for Industry - Contract Manufacturing Arrangements for Drugs: Quality Agreements Read More General Documents Process Validation General Principles and Practices - Life Cycle Approach to Validation Read More Recombinant Proteins & Biologics A-Mab- A Case Study in Risk Based Approach to Bio-process Development Read More Recombinant Proteins & Biologics Points to consider in the Characterization of cell lines used to produce biologicals Read More Recombinant Proteins & Biologics ICH Q10- Guidance for Industry Pharmaceutical Quality System Read More Recombinant Proteins & Biologics ICH Q9- Guidance for Industry Quality Risk Management Read More Recombinant Proteins & Biologics ICH Q8- Guidance for Industry on Pharmaceutical Development Read More Recombinant Proteins & Biologics ICH Q5D - Guideline for Derivation and Characterization of Cell Substrates Read More Recombinant Proteins & Biologics IND application Read More Recombinant Proteins & Biologics Content and Format of IND for Drugs and Well Characterized Biologics Read More BioSimilars Guidance for Industry - Scientific Considerations in Demonstrating Biosimilariy to a Reference Product Read More BioSimilars Guidance for Industry - Demonstrating Biosimiliarity to a Reference Protein Product Read More Cell And Gene Therapy Guidance for Industry - Potency tests for Cellular and Gene Therapy Products Read More Cell And Gene Therapy Application of current statutory authorities to human somatic cell therapy products Read More Cell And Gene Therapy Guidance for Human Somatic Cell Therapy and Gene Therapy Read More Cell And Gene Therapy Guidance for Industry- Minimally manipulated unrelated allogeneic placental umbilical cord blood for hematopoetic reconstitution Read More Cell And Gene Therapy Points to consider in collection, processing and testing of ex-vivo-activated mononuclear leukocytes Read More Cell And Gene Therapy Proposed approach to regulation of cellular and tissue based products Read More Cell And Gene Therapy A-VAX Application of Quality By Design to Vaccines - 2012 Read More

< Back Bispecific antibodies are an expanding therapeutic approach with a key challenge in CMC Jun 17, 2026 Over the past months, we have highlighted how CMC strategies shape the success of modern drug development programs. Today we want to discuss how Bispecific Antibodies (bsAbs) represent another excellent example of this series. Just like with ADC manufacturing, mRNA LNPs, CGTs or CAR-T therapies, as CMC Experts we see how every therapeutic modality introduces their own manufacturing risks, which need to be understood long before they become development bottlenecks. Bispecifics come with their own risks. While their ability to simultaneously engage two different targets creates exciting opportunities across oncology and other therapeutic areas, producing these complex molecules consistently, safely, and at commercial scale becomes a critical challenge. Unlike traditional monoclonal antibodies, bispecific antibodies present additional CMC hurdles due to their asymmetric structures and potential for dimers and mispairing chains during expression. Sophisticated purification approaches, and robust analytical characterization are needed to ensure off target impact does not reduce potency or cause adverse events. These challenges extend throughout the entire product lifecycle. Cell line selection, upstream and downstream process development, analytical strategy, formulation development, and long-term stability all influence the ability to deliver a reliable product. The complexity of bispecific manufacturing is changing CMC strategies and CDMO partnerships. Developers must consider manufacturability, process robustness, analytical control, formulation, and technology transfer early, while CDMOs continue to invest in specialized expression, purification, and analytical capabilities. Delaying these decisions can create avoidable development delays, regulatory challenges, and costly rework. Experienced CMC partners can make the difference between de-risked development and vulnerable strategies. Our Pharmefex team brings expertise spanning antibody development, CMC strategy, regulatory compliance and CDMO alignment to meet your scientific and regulatory goals. As bispecific antibody pipelines continue to grow, the programs most likely to advance efficiently into the clinic and beyond will be those where CMC strategy evolves alongside the molecule itself. #BispecificAntibodies #Antibodies #Biologics #CMC #DrugDevelopment #Biotechnology #Immunotherapy #Bioprocessing #CDMO #RegulatoryStrategy #Pharmefex #consulting #Dahliaconsulting Sources BioProcess International, Process Development, Manufacturing, and Clinical Support for Bispecific Antibodies: Chemistry, Manufacturing, and Controls Considerations https:// www.bioprocessintl.com/process-development/process-development-manufacturing-and-clinical-support-for-bispecific-antibodies-chemistry-manufacturing-and-controls-considerations WHO, Guideline on the Production and Quality Control of Monoclonal Antibodies and Related Products (draft) https://cdn.who.int/media/docs/default-source/biologicals/mabs-manufacture-guideline-draft-for-1st-public-comment.pdf Fortune Business Insights, Bispecific Antibody Market Analysis (2026) WuXi Biologics / Contract Pharma industry reports and commentary on bispecific manufacturing capacity and CMC trends (2026) PatSnap, Bispecific Antibody Patent Landscape Analysis (April 2026) Oxford Academic, publications on bispecific antibody engineering and manufacturing challenges (2024) Previous Next

< Back CAR-T Meets LNP: A Familiar Platform with a New CMC Challenge Jun 10, 2026 Two weeks ago, we wrote about mRNA and LNP platform industrialization and the evolution from pandemic urgency to sustainable and scalable manufacturing guidelines. However, the delivery systems at the center of that article, LNPs and engineered viral vectors, are also appearing in another, different context: in-vivo CAR-T therapy where they are the manufactured product themselves. Notably, formulation science, particle characterization methods, and GMP infrastructure being built for mRNA therapeutics are foundations very similar to those any in-vivo CAR-T program will depend on. This means that the CMC teams working in one program are relevant to the other. However, significantly for CMC, in-vivo CAR-T therapy eliminates the known complexities of conventional autologous therapies: no patient-specific manufacturing cycle, no apheresis, ex-vivo T-cell isolation, activation, expansion or cryopreservation. Instead, the viral vector or LNP carrying the CAR gene is manufactured under GMP conditions, administered directly, and the patient’s own T cells are reprogrammed in the body. A May, 2026 perspective in Nature Signal Transduction and Targeted Therapy estimates a 1.5 to 3-week reduction in manufacturing time, with projected cost reductions of 50% or more per treatment course, compared to traditional CAR-T. Reassuringly, first-in-human clinical data now exists for both lentiviral vector and LNP-based platforms. That said, while in-vivo approaches eliminate ex-vivo cell processing complexity, they introduce new CMC demands on the delivery vector. Batch-to-batch consistency for viral vectors remains technically demanding. Still, two CMC gaps are particularly active at this stage: comparability strategies for in-vivo products are not yet established, and when manufacturing changes occur, which they will, the field will not yet have a standard framework for what adequate comparability data looks like for these modalities. Separately, according to Lu et al., novel analytical methods are needed to assess transduction efficiency, T-cell specificity, and potency in a system in which cells are generated within the patient rather than in a bioreactor. Programs that arrive at these gaps late will face the same friction that slowed early ex-vivo CGT development. At Pharmefex , we have deep practical industry knowledge in viral and non-viral gene delivery, in addition to CAR-T therapy. Our team can provide technical support, or CMC and regulatory support for developing in-vivo CAR-T programs. With experience in viral vectors and LNP modalities, we have the breadth of industry experience, the knowledge to predict development bottlenecks, and the ability to smooth CDMO management. Manufacturing simplicity is a compelling argument for in-vivo CAR-T. To ensure success, it is required that the manufacturing, analytical, and regulatory groundwork is laid before it is needed, not the standard we’ll engage later. #CellTherapy #GeneTherapy #CART #CARTcell #InVivoCART #CMC #LNP #ViralVectors #Biotech #Pharma #DrugDevelopment #RegulatoryStrategy #Manufacturing #Pharmefex #Dahliaconsulting Sources Primary Source: Lu et al. — The In-vivo Revolution in CAR-T Therapy Medicinal Products: Challenges and Regulatory Prospects Nature Signal Transduction and Targeted Therapy, Vol. 11, Article 192 (May 22, 2026). https://www.nature.com/articles/s41392-026-02633-4 Additional Sources: BioInsights, Cell and Gene Therapy Insights 2026 https://www.insights.bio/cell-and-gene-therapy-insights/spotlights/year/2026 FDA: RMAT Designation (Regenerative Medicine Advanced Therapy) https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/regenerative-medicine-advanced-therapy-designation ICH Cell and Gene Therapy Discussion Group (CGTDG) https://www.ich.org/page/cell-gene-therapy-discussion-group Previous Next

< Back CGT Regulatory Flexibility and Global Harmonization May 25, 2026 The FDA’s January 11, 2026 guidance on more flexible CMC approaches for cell and gene therapies, and EMA’s investigational ATMP (Advanced Therapy Medicinal Product) guideline effective July 1, 2025, are cornerstone references for designing phase-appropriate controls, potency assays, comparability plans and global dossier strategies. At Pharmefex, we are actively monitoring and continue to highlight these developments for the community. We can see that regulators are adapting to the realities of CGT development. The FDA’s 2026 communication makes clear that, when scientifically justified, it will allow greater flexibility in clinical development plans, commercial specifications and process- validation protocols. That matters because many CGT programs serve small patient populations, work on compressed timelines and see their manufacturing processes evolve as science advances. To foster earlier dialogue, FDA also points sponsors to its CMC Development and Readiness Pilot (CDRP), which accelerates reviewer engagement for fast-track programs. Similarly, EMA’s investigational ATMP guideline has become a key reference for CGT developers in Europe, providing clear expectations for phase-appropriate controls, potency assays, manufacturing changes, and comparability throughout development. The guideline clarifies how requirements evolve as programs mature, reinforcing the importance of potency, process understanding, and comparability planning. For sponsors, it offers a practical roadmap for building global CMC strategies that support EU clinical trials and eventual worldwide registration. This increased flexibility adds complexity, as both FDA and EMA increasingly expect sponsors to justify CMC decisions early and rigorously, often with different areas of emphasis. At Pharmefex, we’ve been reporting on this previously and are tracking and amplifying these CGT CMC updates because they’re central to our work . We help teams define phase-appropriate CMC roadmaps, plan comparability studies or validation work up front, prepare for FDA and EMA interactions, and identify gaps before they become costly. #CMC #CellTherapy #GeneTherapy #ATMP #RegulatoryStrategy #Biotech #Pharma #Pharmefex Key sources: • FDA CGT CMC Flexibilities: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/flexible-requirements-cell-and-gene-therapies-advance-innovation • FDA CDRP Program: https://www.fda.gov/drugs/pharmaceutical-quality-resources/chemistry-manufacturing-and-controls-development-and-readiness-pilot-cdrp-program • EMA Investigational ATMP Guideline: https://www.ema.europa.eu/en/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials-scientific-guideline Previous Next

< Back mRNA/LNP Manufacturing: From Pandemic Platform to Industrial Discipline May 22, 2026 After the urgent push and approval of mRNA vaccines for COVID-19, more people are thinking of the utility of the space for non-viral gene delivery in general. mRNA technology did not begin with COVID-19, and it did not end with it. The pandemic accelerated investment on an unprecedented scale, and by the time it began to fade, practitioners were writing about mRNA-LNP manufacturing as an established industrial discipline. mRNA vaccines and treatment open the door for quick and flexible approvals/ developments due to the flexible design of mRNA and higher accuracy compared to other forms of gene targeted therapy. A process void of cells, mitigates concerns of pathogens or related microorganisms, risk of transmission of infectious agents compared to traditional vaccine manufacture involving pathogen propagation, and risk of residual live viruses in the product - all of which are part of CMC in other gene editing or antigen treatments. LNPs are a mode of transport for the mRNA into the cell of interest; protecting mRNA from degradation while facilitating its specific cellular uptake and endosome escape. With complexity of mRNA processes plus the LNPs, CMC is crucial and expertise important for manufacturers. CDMOs are building integrated end-to-end GMP capabilities, and the April 2026 LNP Formulation and Process Development Summit confirmed that the scientific foundation is established. The CMC challenges are specific – ie LNP size and morphology control are directly linked to potency and in vivo performance, delivery related to particle engineering and characterization, storage stability, etc. For early-stage programs, deferring the manufacturing conversation for later phases carries risk . With regulatory expectations rising, and FDA/ ICH guidance defining more aspects of what comparability, potency, and process control look like at commercial scale, formulation decisions made in early phase can impact far into the future. At Pharmefex , we support mRNA and LNP programs across the all CMC stages of life: analytical method development, formulation strategy, CDMO selection and governance, IND authoring, and regulatory preparation through first-in-human. We have experts ready to help guide, problem solve and support. The complexity of this platform is well understood. What determines how smoothly a program progresses is how early that understanding is applied. Sources 1. Kalghatgi, S. PhD — mRNA-LNP Vaccine Manufacturing: An In-Depth Examination (LinkedIn, 2023) https://www.linkedin.com/pulse/mrna-lnp-vaccine-manufacturing-in-depth-examination-kalghatgi-phd 2. LNP Formulation & Process Development Summit 2026 https://lnp-formulation-process-development-pharma.com/ #mRNA #LNP #CMC #Biotech #Pharma #DrugDevelopment #NonViralDelivery #Manufacturing #RegulatoryStrategy #Pharmefex Previous Next

< Back ADCs: A Deeper Look at Antibody-Drug Conjugates and Why CMC Preparedness Is Everything May 15, 2026 Last week we touched on ADC manufacturing complexity and why integrated CMC thinking matters. This week we want to go deeper and explore the ADC economy further. ADCs are reshaping oncology as a significant change in how we approach targeted cancer therapy. What makes them scientifically compelling is precisely what makes their development operationally unforgiving. What is an ADC: An ADC combines an antibody that homes in on a tumor-specific antigen, a chemical linker engineered to remain stable in circulation, and an ultrapotent cytotoxic payload released only after internalization by the target cell. Payloads are typically 100 to 1,000 times more toxic than conventional chemotherapy, delivered with a precision that systemic treatment cannot match. ADCs Are Dominating Oncology: The global ADC market reached $13.5 billion in 2025, with 15 FDA-approved products and more than 400 programs in development. Enhertu alone generated $3.75 billion. Analysts project the market at $28 to $39 billion by 2034-2035. The deal landscape reflects this development with BioNTech committing up to $7.6 billion in milestones for a single ADC collaboration with Bristol Myers Squibb. Eli Lilly committed $5 billion to dedicated ADC manufacturing infrastructure. Boehringer Ingelheim paid $1.3 billion for platform company Synaffix. Several factors are driving this development. Broad clinical validation with ADCs having shown efficacy across breast, lung, urothelial, gastric, and hematologic cancers. Enhertu's expansion into HER2-low and HER2-ultralow disease added an estimated 200,000 treatable patients in the U.S. with a single regulatory action. And Padcev plus Keytruda reduced mortality risk by 49% in urothelial cancer. Furthermore, there are three generations of improvement: Early ADCs (Mylotarg, Kadcyla) established proof of concept. Each subsequent generation brought better linker chemistry, antigen selection, and conjugation control. Third-generation molecules with site-specific conjugation and novel payloads have reset expectations for what targeted oncology can achieve. All these developments allow for an expanding target landscape: HER2 remains dominant commercially, but the pipeline has broadened rapidly to TROP2, HER3, B7-H3, CLDN18.2, Nectin-4, and ROR1. Bispecific ADCs targeting dual antigens are entering phase III as a strategy against resistance. Lastly, in the combination with immunotherapy, ADCs can be paired with checkpoint inhibitors, showing synergistic activity across multiple tumor types, pulling the modality into earlier treatment lines and expanding its commercial reach. CMC Preparedness Is Key ADCs carry the full regulatory and manufacturing complexity of both a biologic and a small molecule, plus a third layer: conjugation chemistry that neither traditional CMC framework was designed to address. The antibody intermediate requires cell line development, upstream process control, protein A purification, viral clearance validation, and glycan and charge variant analysis. The linker-payload must meet HPAPI containment standards, often at occupational exposure limits measured in nanograms per cubic meter of air and must be independently validated before conjugation begins. The essential step of conjugation compounds the complexities mentioned above. The drug-to-antibody ratio (DAR) governs clearance rate, efficacy, aggregation, and toxicity. Because DAR is a distribution, not a single value, controlling it across batches, clinical phases, and manufacturing sites requires conjugation chemistry that is well-characterized from the earliest stages of development. Analytical requirements follow: DAR demands mass spectrometry, free payload requires orthogonal chromatography, aggregation needs SEC-MALS or DLS, conjugation site heterogeneity requires peptide mapping. No single method is sufficient, and the Module 3 documentation burden for an ADC IND or BLA is substantially greater than for either an antibody or a small molecule alone. The efforts necessary to satisfy the requirements during manufacturing of ADCs result in significant regulatory stakes. FDA data shows 11 of 32 Complete Response Letters for biologic programs were attributed to CMC deficiencies . ADCs sit at the intersection of biologic and small molecule frameworks, with no ADC-specific CMC guideline from FDA or EMA. Programs that treat the three workstreams as independent, or that engage regulators late, tend to encounter that ambiguity at IND review, at End of Phase 2, or in a CRL. The result of these challenges is that ADC CMC timelines tend to be structurally longer. While stability studies run in real time, GMP scale-up requires process characterization that cannot be compressed. HPAPI linker-payload supply chains have limited sourcing options and long lead times, requiring commitments well ahead of clinical demand. Programs that treat CMC as a Phase 2 problem consistently find that it becomes a Phase 3 crisis. This is where Pharmefex comes in: Our team includes specialists with hands-on experience in antibody development, ADC process development, and lipid nanoparticle systems. We think in the hybrid framework ADC programs require, across both the biologic and small molecule sides of the equation. Our integrated oversight model covers scheduling, logistics, and quality across antibody production, linker-payload synthesis, and conjugation as a single workflow. When an upstream raw material changes, we assess downstream impact before implementation, maintaining consistency as programs scale. We support colocation of antibody production, linker-payload synthesis, and conjugation, reducing inter-site transfer risks and keeping quality management unified across development stages. For programs moving toward IND and beyond, this coordination is where timelines are protected. In summary: The challenge for drug development teams is whether their program is structured to get the molecule to patients, on time, with a regulatory package that holds up. That is the question Pharmefex is built to help answer and where Pharmefex adds value . Sources 1. Drug Discovery News — What are antibody-drug conjugates (ADCs)? Mechanism, pipeline, and outlook (2025): https://www.drugdiscoverynews.com/what-are-antibody-drug-conjugates-adcs-mechanism-pipeline-and-outlook-16778 2. PMC / Frontiers in Oncology — Antibody–drug conjugate: a newly developed biological missile for tumor treatment (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12605357/ 3. PMC — The next frontier in antibody-drug conjugates: challenges and opportunities (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12366496/ 4. Biopharma PEG — ADC Market 2025: Rising Sales and Growing Phase III Pipelines (2025): https://www.biochempeg.com/article/447.html 5. Vision Lifesciences — ADC Market 2026: Antibody-Drug Conjugate Pipeline & Deals: https://visionlifesciences.com/insights/adc-antibody-drug-conjugate-market-licensing 6. Toward Healthcare — Antibody Drug Conjugate Market to Reach USD 32.66 Bn by 2035 (2026): https://www.towardshealthcare.com/insights/antibody-drug-conjugate-market-sizing 7. Grand View Research — Antibody Drug Conjugates Market Size, Top Share, Demand: https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market 8. WuXi XDC — Addressing Bioconjugates Production Challenges and Accelerating Drug Development (Dec 2024): https://wuxixdc.com/addressing-bioconjugates-production-challenges-and-accelerating-drug-development/ 9. Parexel — Challenges and best practices for developing Antibody-Drug Conjugates (ADCs): https://www.parexel.com/insights/blog/challenges-and-best-practices-for-developing-antibody-drug-conjugates-adcs-1 10. APC — Biologics in FDA's 2025 Approvals: Implications for Future CMC Strategies: https://approcess.com/blog/biologics-in-fdas-2025-approvals-implications-for-future-cmc-strategies 11. Quality Executive Partners — ADCs Unleashed: Navigating Development Hurdles in Targeted Cancer Therapy (2025): https://www.qualityexecutivepartners.com/press/adcs-unleashed-navigating-development-hurdles-in-targeted-cancer-therapy #ADC #AntibodyDrugConjugates #CMC #Oncology #DrugDevelopment #Biotech #Pharma #CDMO #RegulatoryStrategy #Manufacturing #ClinicalDevelopment #Pharmefex Previous Next

< Back ADCs: Why the Most Exciting Modality in Oncology Is Also the Most CMC-Demanding May 15, 2026 A Pharmefex Thought Leadership Article ADCs have become a defining modality of oncology investment. The global market reached $13.5 billion in 2025, with 15 FDA-approved products and more than 400 programs in development. BioNTech committed up to $7.6 billion in milestones for a single collaboration. Eli Lilly pledged $5 billion to dedicated ADC manufacturing infrastructure. The clinical results are supporting the enthusiasm: Enhertu's expansion into HER2-low disease added 200,000 newly treatable patients in the U.S. with a single regulatory action. What makes ADCs work is an antibody targeting a tumor-specific antigen, a linker engineered to stay stable in circulation, and a cytotoxic payload released only after internalization. Payloads are 100 to 1,000 times more toxic than conventional chemotherapy, delivered with precision systemic treatment cannot match. What makes them difficult to develop is that they carry the full CMC complexity of both a biologic and a small molecule, plus a third layer: conjugation chemistry that neither framework was designed to address. The antibody requires biologic-grade process control. The linker-payload must meet HPAPI containment standards. And conjugation must produce a consistent drug-to-antibody ratio across batches, clinical phases, and sites. No single analytical method covers all of this. FDA data shows 11 of 32 Complete Response Letters for biologic programs were attributed to CMC deficiencies. ADCs face that same scrutiny with no ADC-specific CMC guideline from FDA or EMA. Programs that treat CMC as a Phase 2 problem consistently find that it becomes a Phase 3 crisis. At Pharmefex , we support ADC programs with integrated oversight across antibody production, linker-payload synthesis, and conjugation as a single workflow, with specialists who think across both the biologic and small molecule sides of the equation. The full article explores what that means in practice. #ADC #AntibodyDrugConjugates #CMC #Oncology #DrugDevelopment #Biotech #Pharma #CDMO #RegulatoryStrategy #Pharmefex Previous Next

< Back ADCs: Manufacturing Challenges and Opportunities Jan 28, 2026 Antibody–drug conjugates have moved into a major focus across oncology pipelines. The ADC approach pairs targeted delivery with potent payloads, and less off-target effects than standard of care (chemotherapy), which shows tremendous clinical value. Now, maturing programs are shifting focus from discovery to CMC. Leading conversations are topics on sourcing constraints, difficulty with scale-up while maintaining consistency, complex analytical methods, and the difference in treatment of fill-finishes compared to standard biologics - all aspects of CMC. As many companies move to the outsourced development and manufacturing model, using CDMOs, these technical complexities are even more relevant to manage. Shifting the discussion to having unified CMC and quality management, consistent reliable technology transfer and supply chain design, all easier with one-stop shop CDMOs. Colocation of all integral aspects, reduces transport risks, simplifies coordination and maintains consistency across development stages. Ensuring quality systems, CDMO management and processes are up to standards is key to success. In summary: ADC development requires a system-level approach. Treating individual elements of this process in isolation creates gaps that tend to surface later and programs that align conjugation strategy, analytical methods, supply chain, and drug product considerations early are better positioned as they move toward clinical and commercial stages. As demand for ADCs continues to grow and the investment in manufacturing infrastructure is following. The remaining question is how effectively that complexity is managed at the program level. At Pharmefex, we work with teams navigating exactly these challenges. Our group includes specialists with direct experience in antibody and ADC development/LNP conjugation, along with quality management systems, supply chain, and analytical development. This allows us to support programs from a practical CMC perspective, where decisions around conjugation, analytics, and supply chain are closely connected. We support clients through the development and regulatory process by providing integrated program oversight , where complex considerations are managed across antibody, linker, payload, and drug product activities. Changes in raw materials or upstream processes are assessed for downstream impact before they are implemented, helping maintain consistency as programs scale. For teams working on ADCs, this level of coordination tends to make a difference when moving toward IND and beyond. The complexity is inherent to the modality. How it is managed determines how smoothly a program progresses. #ADC #Biotech #Pharma #CMC #DrugDevelopment #AntibodyDrugConjugates #Manufacturing #CDMO #Quality #RegulatoryStrategy #Pharmefex #consulting #management #programmanagement #DahliaConsulting Previous Next

< Back Early CMC readiness is front and center across the entire industry Jan 21, 2026 Early CMC readiness is a hot topic across pharma. Large companies, emerging biotech, and different modalities are facing the same pressure. Even in areas like radiopharmaceuticals, where constraints are more visible, the message holds to address CMC early or deal with it later under pressure. Recent FDA activity reinforces this shift. With the CMC Development and Readiness Pilot and further strategy directions expected in 2026, there is a push toward earlier manufacturing readiness for accelerated programs. Similar fast-track approaches are emerging internationally, adding complexity for globally positioned teams. In many early-stage programs, CMC is still treated as a later step. We see this often. Teams delay engagement, either to conserve resources or due to limited visibility into its impact. As a result, gaps appear in analytics, quality systems and documentation, or CDMO alignment creates friction and delay, most often causing the most damage when timelines tighten. Programs like the FDA pilot enable earlier regulatory engagement, however, this only works when the underlying CMC strategy is already defined . Analytical planning, quality design, downstream development, timelines, and CDMO strategy need alignment upfront. At Pharmefex , we support early biotech teams in building that structure. From CMC strategy and CDMO management to IND preparation and early FDA interaction, the focus is on enabling progress without unnecessary rework or delay. Early FDA feedback helps. Early CMC engagement determines whether that feedback can be used effectively. We can help you along the way, regardless of where you are in the development phase. Contact us to learn how we might be able to help. Sources U.S. Food and Drug Administration Industry perspective on early CMC readiness across modalities https://www.linkedin.com/pulse/get-ahead-cmc-hurdles-before-derail-your-ind-nucleus-radiopharma-q824c/ #CMC #Biotech #Pharma #DrugDevelopment #RegulatoryStrategy #IND #Pharmefex Previous Next